DNA/RNA

Description
Protein
Note
The C-terminus of TIG3 is believed to be a membraneanchoring domain which is involved in driving membrane localization and is also required for centrosome localization. Removal of this domain from TIG3 causes it to distribute diffusely throughout the cytoplasm and reduces its ability to decrease cell survival Sturniolo et al., 2003; Sturniolo et al., 2005; Jans et al., 2008; Tsai et al., 2009 
Expression
Ubiquitously expressed; expression is reduced in hyperproliferative diseases including cancer.
Localisation
Cell membrane, centrosome (Scharadin et al., 2011) .
Function
TIG3 is a type II tumor suppressor gene which regulates cell proliferation and survival (DiSepio et al., 1998) . Loss of TIG3 expression leads to hyperproliferative diseases including psoriasis and cancer. Restoration of TIG3 expression to cancer cell lines decreases cell cycle progression and induces apoptosis causing an overall decrease in viable cells (DiSepio et al., 1998; Huang et al., 2002; Higuchi et al., 2003; Tsai et al., 2009; Scharadin et al., 2011) . Localization of TIG3 to the centrosome is believed to be responsible for this decrease in cell survival, which leads to an increase in p21 level, a G1/S phase block, an activation of the caspase cascade, and a reorganization of the microtubule network (Scharadin et al., 2011) . In contrast, expression of TIG3 in normal keratinocytes induces a process of terminal differentiation through the binding to and activation of type I transglutaminase and increase in cornified envelope formation to decrease cell survival (Sturniolo et al., 2003; Sturniolo et al., 2005; Jans et al., 2008) . Localization of TIG3 to the cell membrane in keratinocytes is necessary for it to bind type I transglutaminase. Homology TIG3 shares homology with the H-rev107 family of class II tumor suppressors and the NlpC/P60 superfamily (Hajnal et al., 1994; DiSepio et al., 1998; Husmann et al., 1998; Anantharaman and Aravind, 2003; Jahng et al., 2003) .
Mutations
Note No known mutations.
Implicated in
Various cancers
Note TIG3 expression is reduced in several cancer including breast, skin, lymphoma, leukemia, kidney, ureter, colorectal, liver, biliary tract, ovary, and uterine.
Disease
Cancer is a disease characterized by uncontrolled cell proliferation. Prognosis Cancer prognosis is dependent upon several tumorspecific conditions, including location, size, and metastasis. Oncogenesis Loss of TIG3 mRNA and protein expression is observed in several cancers and may be necessary for oncogenesis (DiSepio et al., 1998; Casanova et al., 2001; Duvic et al., 2003; Shyu et al., 2003; Jiang et al., 2005; Lotz et al., 2005; Shyu et al., 2005) . Tazarotene treatment of skin cancers leads to increased TIG3 expression and reduced proliferation (Duvic et al., 2000; Duvic et al., 2003) . The loss of TIG3 is associated with increased cell proliferation and TIG3 loss may be necessary for cancer progression.
Hyperproliferative diseases
Note
Loss of TIG3 expression is associated with hyperproliferative diseases including psoriasis and cancer. TIG3 mRNA and protein levels are reduced in psoriatic lesions. Treatment with tazarotene leads to an increase in TIG3 levels and restoration of the normal epidermal condition (Duvic et al., 2000) . Hypermethylation of the TIG3 promoter is a possible mechanism for reduced expression in psoriasis (Kwong et al., 2005) . Disease Psoriasis is a common disorder of the skin which is characterized by inflammation and hyperproliferation of the epidermis. Prognosis Psoriasis is a non-fatal, chronic disorder that can be controlled with treatment.
Breakpoints
Note No breakpoints known.
